Pathos AI Raises $237M Series E at About $3B Post-Money, Led by Bristol Myers Squibb

Pathos AI, a New York company that builds AI tools for drug development, closed a $237 million Series E round led by Bristol Myers Squibb. The company announced the round on 23 October 2026 and put the post-money valuation at approximately $3 billion. A drugmaker leading the round is a strategic investment, which reads differently from a round led by a venture firm.

The company's release is the primary source for the amount, the lead, the valuation and the date, and Venture Capital Tracker repeats those figures. The valuation is the least certain figure, because the release itself says "approximately." Each section below takes one question a reader is likely to ask and answers it from the sources, marking which parts are the company's claims and which are our arithmetic.

How much did Pathos AI raise and who led it?

Pathos AI raised $237 million in a Series E round, according to its company release dated 23 October 2026. The release says Bristol Myers Squibb (NYSE: BMY) led the round.

What does Pathos AI do?

Pathos AI runs a platform called Foundry. The company says Foundry uses thousands of specialized AI agents to gather and synthesize clinical, genomic and competitive information for drug programs in real time. The company says it does not design drugs from scratch. It uses AI to choose clinical assets, make portfolio decisions and guide trials.

The distinction matters for how the business should be judged. A company that picks which drugs to pursue earns or loses value through those choices, and the results of trials are the only evidence that the choices were good. The reported figures give no trial results, so the platform's value is, for now, the company's own description of it.

Its clinical-stage oncology pipeline has four active assets: JSKN016, pocenbrodib, AZD4241 and DO-2. The company describes JSKN016 as a first-in-class TROP2/HER3 bispecific antibody-drug conjugate. It describes AZD4241 as a novel ER PROTAC and DO-2 as a next-generation MET kinase inhibitor.

Why would a drugmaker lead a startup round?

A drugmaker that leads a round brings more than cash. The company announced the investment alongside a partnership with Bristol Myers Squibb and Tempus AI for neurological drug development, including Alzheimer's disease. That ties the investor to Pathos AI's work, which a financial investor buying equity alone does not do.

The reported figures do not say how much of the $237 million Bristol Myers Squibb invested. They also do not give the terms of the partnership.

A reader should keep the two apart. The equity investment is one transaction, and the partnership is a separate arrangement with its own scope, which the reports describe only in general terms.

What does the $3 billion valuation mean?

A post-money valuation includes the new money. The company's figure of approximately $3 billion therefore includes the $237 million. Subtracting the round gives a pre-money value of about $2.76 billion. The company did not state that figure. It is our calculation from the reported numbers.

The valuation needs a reference point before it means much. The sources give only the post-money figure and the new money, so the share of the company sold in the round is the only other ratio we can calculate from them. Both calculations rest on the word "approximately," so each result carries the same uncertainty as the release.

A Series E is a private financing, so the $3 billion is the price set in this round, not a market value. For how round size differs from total funding raised, see Round Size vs Cumulative Funding.

Who has reported the round?

Pathos AI announced the round in its release on 23 October 2026. Venture Capital Tracker reported the $237 million amount, the approximately $3 billion valuation and the lead on 23 October 2026.

The release framed the round around the platform and the oncology pipeline. Venture Capital Tracker's account repeats the release's figures and adds that the round was led by Bristol Myers Squibb alongside unnamed existing investors. Readers who want the company's exact wording should go to the release.

What will the money be used for?

Pathos AI says the capital will scale its Foundry platform and speed clinical development of its AI-steered oncology portfolio. The company names JSKN016 as a key priority, with the aim of taking it toward registrational studies. The company also says the funding will support pocenbrodib in mCRPC and RRMM, AZD4241 and DO-2.

The use of funds has two parts. The first is building the software that selects and steers the assets. The second is paying for the clinical work that tests them. The release names both, but it does not divide the $237 million between them, and that split would tell a reader more about the company's priorities than any single program name.

What would change the picture?

The company's own release is not the only view. The competitive field for AI-driven drug discovery is crowded, with many biotech and pharmaceutical companies investing in similar platforms. Pathos AI's success depends on turning its platform insights into clinical outcomes and standing apart from that field. Drug development is also expensive and heavily regulated. The company carries those costs for its own pipeline, and AI guidance on which programs to pursue does not remove them.

What's still unclear?

• The valuation is approximate. The release says "approximately $3 billion." No exact or pre-money figure appears in the company's statement.
• Bristol Myers Squibb's stake is not sized. The reported figures do not say how much of the round it funded or what rights it received.
• The platform and pipeline claims are the company's own. The release describes Foundry's capabilities and the trial goals. Neither the release nor the reports show clinical results.
• The weakest point is the gap between funding and outcomes. The round pays for clinical work. It does not show that any program will succeed, and drug development carries high failure rates.
• No use-of-funds split is given. The release names the platform and the trials but does not say how the $237 million is divided between them.